Skip to main content
search here
username password
Macmillan and Cancerbackup merged in 2008. Together we provide free, high quality information for people affected by cancer through our publications, website and phone service. Find out more| .
How we produce our information|
Imatinib| is the main type of treatment for chronic myeloid leukaemia. It is a type of drug known as a signal transduction inhibitor and is taken as capsules that are swallowed.
Imatinib works by blocking (inhibiting) signals within the leukaemia cells that make them become abnormal and continue to grow and divide. Blocking the signals makes the cells die.
The National Institute for Health and Clinical Excellence (NICE) have recommended that imatinib should be the first treatment considered in the chronic phase of CML. People in the chronic phase, who are already being treated with interferon, can discuss switching to imatinib with their specialist. Imatinib can also be used in the accelerated or blast crisis phases of CML, as long as it hasn’t been used before.
The side effects of imatinib are usually mild and treatable. Side effects include:
Posted by Dianne J
Posted by bob jk
Posted by lesley22
If you have any questions about cancer, need support or just want someone to talk to, ask Macmillan.
Browser does not support script.